相似文献
1
Sir David Jack: an extraordinary drug discoverer and developer.大卫·杰克爵士：一位杰出的药物发现者和开发者。
Br J Clin Pharmacol. 2013 May;75(5):1213-8. doi: 10.1111/j.1365-2125.2012.04467.x.
2
A century of asthma.哮喘的一个世纪。
Am J Respir Crit Care Med. 2004 Aug 1;170(3):215-21. doi: 10.1164/rccm.200402-185OE.
3
James Whyte Black. 14 June 1924-22 March 2010.詹姆斯·怀特·布莱克。1924年6月14日 - 2010年3月22日。
Br J Pharmacol. 2010 Jul;160 Suppl 1(Suppl 1):S3-4. doi: 10.1111/j.1476-5381.2010.00844.x.
4
Asthma among the famous. Roger E. C. Altounyan (1922-1987) British physician and pharmacologist.
Allergy Asthma Proc. 1998 Sep-Oct;19(5):328-32.
5
[IgE and Anti-IgE in Asthma: A Chequered History].[哮喘中的IgE与抗IgE：一段波折的历史]
Pneumologie. 2017 Jun;71(6):398-405. doi: 10.1055/s-0043-102070. Epub 2017 Jun 26.
6
Blocking asthmatic progression and chronicity in the pre-corticosteroid era.在皮质类固醇激素时代之前阻断哮喘的进展和慢性化。
J Allergy Clin Immunol. 2008 Mar;121(3):787-90. doi: 10.1016/j.jaci.2008.01.024.
7
[Chronology of asthma medications].[哮喘药物治疗时间线]
Rev Alerg Mex. 1999 Nov-Dec;46(6):152-4.
8
Pulmonary clinical pharmacy practice.
Ann Pharmacother. 2006 Jul-Aug;40(7-8):1407-8. doi: 10.1345/aph.1G484. Epub 2006 Jun 27.
9
Asthma: one hundred years of treatment and onward.哮喘：百年治疗历程及展望
Am J Respir Crit Care Med. 2005 Jun 1;171(11):1202-8. doi: 10.1164/rccm.200502-257OE. Epub 2005 Mar 18.
引用本文的文献
1
It is time to end our love affair with short-acting β-agonists in asthma.是时候结束我们在哮喘治疗中对短效β受体激动剂的过度依赖了。
ERJ Open Res. 2022 Oct 17;8(4). doi: 10.1183/23120541.00353-2022. eCollection 2022 Oct.
本文引用的文献
1
Pharmacology and therapeutics of bronchodilators.支气管扩张剂的药理学和治疗学。
Pharmacol Rev. 2012 Jul;64(3):450-504. doi: 10.1124/pr.111.004580. Epub 2012 May 18.
2
Evaluation of treatment continuation with alosetron by IBS-D severity criteria.根据 IBS-D 严重程度标准评估阿洛司琼的治疗持续时间。
Curr Med Res Opin. 2012 Mar;28(3):449-56. doi: 10.1185/03007995.2011.653435. Epub 2012 Feb 7.
3
Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma.评估在吸入性糖皮质激素中添加长效β2受体激动剂治疗哮喘的安全性。
N Engl J Med. 2011 Jun 30;364(26):2473-5. doi: 10.1056/NEJMp1104375.
4
The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy?美国食品药品监督管理局与长效β2受体激动剂：在治疗的风险与益处之间达成恰当平衡的重要性？
J Allergy Clin Immunol. 2010 Sep;126(3):449-52. doi: 10.1016/j.jaci.2010.05.039. Epub 2010 Aug 7.
5
The discovery and development of the triptans, a major therapeutic breakthrough.曲坦类药物的发现与研发，是一项重大的治疗突破。
Headache. 2008 May;48(5):685-7. doi: 10.1111/j.1526-4610.2008.01097.x.
6
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one].两种新型长效磷酸二酯酶3/4抑制剂RPL554 [9,10-二甲氧基-2(2,4,6-三甲基苯基亚氨基)-3-(N-氨基甲酰基-2-氨基乙基)-3,4,6,7-四氢-2H-嘧啶并[6,1-a]异喹啉-4-酮]和RPL565 [6,7-二氢-2-(2,6-二异丙基苯氧基)-9,10-二甲氧基-4H-嘧啶并[6,1-a]异喹啉-4-酮]的药理学。
J Pharmacol Exp Ther. 2006 Aug;318(2):840-8. doi: 10.1124/jpet.105.099192. Epub 2006 May 8.
7
Excitation of rat colonic afferent fibres by 5-HT(3) receptors.5-羟色胺（5-HT）3受体对大鼠结肠传入纤维的兴奋作用
J Physiol. 2002 Nov 1;544(3):861-9. doi: 10.1113/jphysiol.2002.025452.
8
How it started.事情是如何开始的。
Cephalalgia. 2001;21 Suppl 1:2-5. doi: 10.1046/0333102401021s0102.
9
5-HT(3) and histamine H(1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats.5-羟色胺（3）和组胺H（1）受体介导大鼠传入神经对肠道过敏反应的敏感性。
Gastroenterology. 2000 Nov;119(5):1267-75. doi: 10.1053/gast.2000.19461.
10
Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.综述文章：5-羟色胺3受体拮抗剂在肠易激综合征治疗中的潜在疗效
Aliment Pharmacol Ther. 1999 May;13 Suppl 2:31-8.
Zotero 插件